Menu Search
Equities

Venus Medtech Hangzhou Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2500:HKG.HZ

Venus Medtech Hangzhou Inc

Actions
  • Price (HKD)2.86
  • Today's Change0.04 / 1.42%
  • Shares traded183.00k
  • 1 Year change-49.11%
  • Beta0.9765
Data delayed at least 15 minutes, as of Feb 16 2026 02:38 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Venus Medtech Hangzhou Inc is a China-based company principally engaged in the research and development, and the manufacture and sale of bioprosthetic heart valves. The Company mainly engages in minimally invasive medical devices and auxiliary instruments and equipment for the treatment of heart valve diseases. The Company provides interventional heart valve devices for valvular heart disease including aortic valve, pulmonic valve, mitral valve and tricuspid valve, a radio frequency ablation system for interventional treatment of HCM, a renal artery denervation ultrasound ablation system for interventional treatment of hypertension and other accessory consumables. The Company's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8/TAV8 and TriGUARD3 Cerebral Embolic Protection Device. The Company mainly conducts its businesses in the domestic market and overseas markets.

  • Revenue in HKD (TTM)483.35m
  • Net income in HKD-726.97m
  • Incorporated2009
  • Employees605.00
  • Location
    Venus Medtech Hangzhou IncRoom 311, 3/F, Block 2, No. 88Jiangling Road, Binjiang DistrictHANGZHOU ChinaCHN
  • Websitehttps://www.venusmedtech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.